# Anti-TACE [D1(A12)] rAb

Catalogue number: 152045 Sub-type: Primary antibody Images:

### Contributor

Inventor: Christopher Tape ; Gillian Murphy Institute: Cancer Research UK, Cambridge Institute, England Images:

### **Tool details**

### **\*FOR RESEARCH USE ONLY**

Alternate name: Anti-TACE [D1(A12)] Class: Recombinant Conjugate: Biotin Description **Description:** Anti-TACE [D1 (A12)] is a human recombinant antibody. This antibody displays inhibitory behaviour to TNF-alpha converting enzyme (TACE). TACE is a membrane-bound metalloprotease (ADAM17) proved capable of cleaving a variety of pathologically significant substrates. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. D1(A12) binds a cross-domain epitope. D1(A12) is the first ADAM inhibitor to show an affinity preference for the complete TACE ectodomain over the isolated catalytic domain. This antibody is a selective TACE antagonist and provides a unique alternative to small molecule metalloprotease inhibition. This antibody allows the study of the individual pathological impact of TACE activity. **Purpose:** 

Parental cell: Organism: **Tissue:** Model: Gender: Isotype: IgG1 Reactivity: Human Selectivity: Host: Human Immunogen: Recombinant human ADAM17 (TACE) ectodomain tagged to biotin. Immunogen UNIPROT ID: Sequence: Growth properties:

Production details: Formulation: Recommended controls: Brain, heart, kidney, liver, lung and spleen **Bacterial resistance:** Selectable markers: Additional notes:

### **Target details**

Target: TACE (ADAM17)

#### **Target alternate names:**

Target background: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule meta...

Molecular weight: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated Cancer

Ic50:

## **Applications**

Application: Fn **Application notes:** 

## Handling

Format: Liquid Concentration: 5.9 mg/ml Passage number: Growth medium: **Temperature:** Atmosphere: Volume: Storage medium: Storage buffer: PBS Storage conditions: -15° C to -25° C Shipping conditions: Shipping at 4° C

### **Related tools**

Related tools: Anti-TACE, Recombinant [D1 (A12)] (mouse IgG)

### References

**References:** 

